ANNEX 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE 
MEMBER STATES 
The Member States should ensure that all conditions or restrictions with regard to the safe and 
effective use of the medicinal product described below are implemented: 
The Member States shall ensure that the Marketing Authorisation Holder (MAH) will provide all 
physicians who are expected to prescribe/use Aclasta in the authorised indications of treatment of 
osteoporosis in post-menopausal women and in men at increased risk of fracture, including those with 
a recent low-trauma hip fracture, and treatment of osteoporosis associated with long-term systemic 
glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture with an 
updated physician information pack containing the following: 
  Physician educational material 
  Patient information pack 
The physician educational material should contain the following key elements: 
  The Summary of Product Characteristics 
  Reminder card with the following key messages: 
o  Need to measure serum creatinine before treatment with Aclasta 
o  Contraindication in patients with creatinine clearance < 35 ml/min 
o  Contraindication in pregnancy and in breast-feeding women due to potential 
teratogenicity 
o  Need to ensure appropriate hydration of the patient 
o  Need to infuse Aclasta slowly over a period of no less than 15 minutes 
o  One-yearly dosing regime 
o  Adequate calcium and vitamin D intake are recommended in association with Aclasta 
administration.  
o  Need for appropriate physical activity, non-smoking and healthy diet 
  Patient information pack 
The patient information pack should be provided and contain the following key messages: 
  Package leaflet 
  Contraindication in patients with severe kidney problems 
  Contraindication in pregnancy and in breast-feeding women 
  Need for adequate calcium & vitamin D supplementation, appropriate physical activity, non-
smoking and healthy diet 
  Key signs and symptoms of serious adverse events 
  When to seek attention from the health care provider 
2 
 
 
 
 
 
 
 
